Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center, focusing on innovative treatment solutions for brain tumor patients [1][2]. Group 1: Strategic Cooperation - The cooperation aims to build a high-level radiotherapy platform centered on specialized treatment for brain tumors, utilizing the ZAP-X radiotherapy robot [1][2]. - The partnership is seen as a new starting point for both parties, with aspirations to enhance diagnostic and treatment capabilities in the field of oncology, particularly for brain tumors [2]. Group 2: Technology and Innovation - The ZAP-X technology is described as revolutionary in the field of cranial radiotherapy, significantly improving the precision and safety of brain tumor treatments [2]. - ZAP-X employs a unique dual-rotating spherical structure, allowing X-rays to target tumors from thousands of non-coplanar angles, effectively destroying tumors while protecting surrounding healthy brain tissue [2]. - The device has achieved approvals in 24 countries and regions globally, with over 5,000 clinical treatments completed [2]. Group 3: Company Development - Baiyang Pharmaceutical is advancing its transformation into a technology-driven enterprise, focusing on optimizing medical scenarios through technological innovation [3]. - The company has established a comprehensive industrial chain in the radiotherapy field, covering research and development, production, and operation [3]. - Baiyang aims to continue building precision radiotherapy centers and applying advanced radiotherapy equipment in clinical settings to benefit more patients in China [3].

Core Viewpoint - The strategic partnership between Baiyang Pharmaceutical and Peking University International Hospital aims to establish a precision radiotherapy center focused on brain tumor treatment, utilizing the ZAP-X robotic system to enhance treatment efficacy and safety for patients [1][2] Group 1: Partnership and Collaboration - Baiyang Pharmaceutical signed a strategic cooperation agreement with Peking University International Hospital to jointly build a precision radiotherapy center [1] - The center will leverage the ZAP-X robotic system, which is recognized as a revolutionary technology in cranial radiotherapy, to improve the precision and safety of brain tumor treatments [1] Group 2: Market Context and Technology - Brain tumors present a global treatment challenge, with traditional surgical methods often leading to secondary injuries such as nerve damage or cerebral edema [1] - The ZAP-X system has been approved for use in 24 countries and regions worldwide, having completed over 5,000 clinical treatments, showcasing its effectiveness in the field [1] Group 3: Future Plans and Vision - Baiyang Pharmaceutical aims to enhance the accessibility of high-quality medical resources and continue the development of the precision radiotherapy center, applying more advanced radiotherapy equipment in clinical settings [2] - The collaboration is seen as a stepping stone for future partnerships in critical areas, with a focus on building a leading medical model that prioritizes technology, service, and patient experience [1]

Core Viewpoint - The company has signed a cooperation agreement with Peking University International Hospital to jointly establish and operate a radiosurgery treatment center, focusing on innovative solutions for brain tumor patients [1] Group 1: Partnership Details - The cooperation agreement was signed on October 23, 2025, in Beijing [1] - The partnership aims to leverage resource complementarity and synergistic advantages to build a high-level radiotherapy platform [1] - The agreement outlines the rights and obligations of both parties in the collaboration [1] Group 2: Technological Focus - The center will utilize the ZAP-X Mars Rover radiosurgery robot operated by the company [1] - The focus will be on "specialized treatment for specialized diseases," particularly targeting brain tumors [1] - The initiative aims to optimize the precision radiotherapy scenarios for brain tumor patients, providing innovative treatment solutions for millions [1]

Core Insights - Baiyang Pharmaceutical has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center focused on brain tumors [1][3] - The ZAP-X device, operated by Baiyang, is designed to enhance the precision and safety of brain tumor radiotherapy, addressing the increasing incidence of brain metastases in China, which exceeds 1.5 million new cases annually [3] Group 1 - The collaboration aims to create a high-level radiotherapy platform that specializes in the treatment of brain tumors [1][3] - The ZAP-X device features an innovative dual-rotating spherical structure that allows X-rays to target tumors from thousands of non-coplanar angles, concentrating radiation on the tumor while minimizing exposure to surrounding healthy tissue [3] - ZAP-X has received regulatory approval in 24 countries and regions worldwide, with over 5,000 clinical treatments completed to date [3] Group 2 - Baiyang's chairman, Fu Gang, emphasized that this partnership is a significant step towards enhancing the clinical application of advanced radiotherapy equipment and improving access to quality medical resources [3]

10月23日，百洋医药与北京大学国际医院签署战略合作协议，共建精准放疗中心。该中心即将落地北京 大学国际医院，依托百洋医药运营的ZAP-X火星舟放射外科机器人（简称"ZAP-X"），打造以脑肿 瘤"专病专治"为核心的放疗平台，优化脑肿瘤精准放疗场景。 ...

Core Viewpoint - The company has signed a cooperation agreement with Peking University International Hospital to establish and operate a radiosurgery treatment center, enhancing the accessibility of quality medical resources [1] Group 1: Agreement Details - The cooperation agreement was signed on October 23, 2025, and has a duration of eight years from the date of signing [1] - The agreement includes clear provisions regarding termination and exit mechanisms, liability for breach, and dispute resolution [1] Group 2: Impact on Company - This collaboration is expected to improve the company's sustainable profitability and have a positive impact on its performance [1]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号： | 2025-089 | | --- | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | | 二、交易合作方介绍 （一）基本情况 单位名称：北京大学国际医院 法定代表人：梁军 开办资金：15,000 万人民币 青岛百洋医药股份有限公司 关于签署合作协议的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次协议签署概况 为推动高端放疗设备临床落地、提高优质医疗资源可及性，发挥双方的资源 优势，青岛百洋医药股份有限公司（以下简称"公司""百洋医药"）与北京大学 国际医院（以下简称"北大国际医院"）于 2025 年 10 月 23 日在北京市签署了《放 射外科治疗中心合作协议》，约定双方通过资源互补、优势协同的方式开展合作， 共同建设并运营放射外科治疗中心，并对双方合作方式等权利义务作出明确约定。 本次签署协议审批权限在总经理权限范围内，公司已履行了签署本协议的内 部审批程序，无需公司董事会及股东会审议批准。 住所：北京市昌平区 ...

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.77% on October 17, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed mixed performance, with Jianfa Zhixin rising by 4.20% to a closing price of 28.05, while Baiyang Pharmaceutical fell by 3.09% to 25.75 [1][2] - Other notable performers included Yifeng Pharmacy (+1.19%), Dacilin (+1.10%), and Dajia Weikang (+0.35%) [1][2] Trading Volume and Value - Jianfa Zhixin had a trading volume of 194,100 shares and a transaction value of 547.1 million yuan, while Baiyang Pharmaceutical had a trading volume of 33,700 shares and a transaction value of 118.76 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 246 million yuan from institutional investors, while retail investors contributed a net inflow of 220 million yuan [2][3] - Notable capital flows included Jianfa Zhixin with a net inflow of 44.84 million yuan from institutional investors, while Baiyang Pharmaceutical experienced a net outflow of 964,800 yuan [3]

尽管放射外科技术(SRS)已应用数十年，但由于成本、设施与技术问题，仍有近80%患者无法获得高质 量治疗，尤其在良性脑肿瘤、恶性脑肿瘤(多为脑转移瘤)等疾病的治疗方面。 本报讯(记者刘钊)近日，全球规模最大、影响力最广的放射肿瘤学学术盛会——第67届美国放射肿瘤学 会(ASTRO)年会在美国旧金山隆重召开，汇聚了超1万名来自世界各地的顶尖放疗专家、学者。青岛百 洋医药（301015）股份有限公司(以下简称"百洋医药")投资企业——放射外科领域创新者ZAP Surgical 携全球领先的脑肿瘤精准放疗机器人ZAP-X火星舟放射外科机器人首次亮相大会，全面展示了ZAP-X的 最新技术突破与临床成果。 在大会现场，ZAP Surgical创始人兼首席执行官、射波刀发明人约翰艾德勒(JohnR.Adler)分享了ZAP-X 的诞生初衷与技术理念，吸引众多专家学者驻足观摩与交流。现场，一项经同行评审的全新科学研究1 也同步发布。该研究由斯坦福大学、迈阿密癌症研究所等多家机构共同参与完成，结果表明：不同平台 间对健康脑组织的低剂量辐射溢出存在显著差异，最高可达到50倍的差异。ZAP-X在进行脑肿瘤放疗 时，对健康脑组织的 ...